Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFG |
dARK ID: | ark:/38995/00130000002dn |
Texto Completo: | http://repositorio.bc.ufg.br/tede/handle/tde/2087 |
Resumo: | Olanzapine is an antipsychotic active ingredient and its marketing in Brazil, in the form of terminated product, is protected by patent up to 2011. As it is recent in the pharmaceutical market and there is not a methodology described in officials forms that is capable of assuring the quality of new formulations, the objective of this paper was to characterize Olanzapine physical-chemical parameters, to develop and validate, in accordance with RE N°899, from May 29 th 2003, the analytical methodology for assay and dissolution and to apply the developed and validated methodologies in the pharmacotechnical development of tablets. It was characterized some physicalchemical parameters of solubility and of light absorption (from 200 to 400nm) in several solvents and it was developed and validated assay and dissolution methodologies by spectrophotometry with ultraviolet detection (UV) and the assay by high efficiency liquid chromatography with ultraviolet detection (HPLC-UV) for the quantification of olanzapine present in film coated tablets of 2.5, 5.0 and 10.0mg. The active ingredient presented a low solubility in water and the wave lengths of maximum light absorption were within the range of 254 and 273nm. For the dissolution methodology by UV spectrophotometry, the parameters were chloride acid 0.1 mol/L as the dissolution media, volume of 1,000mL (5 and 10mg of Olanzapine) and 500mL (2.5mg of Olanzapine), apparatus II (paddles) and a rotation of 50 rpm. The spectrophotometric parameters were chloride acid 0.1 mol/L as blank and 259nm of wave length. For the assay methodology by UV spectrophotometry, it was used as a solvent and as a blank solution chloride acid 0.1 mol/L and a wave length of 259nm. It was used a ProStar 210 UV/VIS VARIAN high efficient liquid chromatographer, a C18 (150x4,6)mm 5μm column in room temperature (25ºC), a flux of 0,8mL/min, a wave length of 254nm and a mobile phase constituted of a mixture of monobasic potassium phosphate buffer 0,01 mol/L pH 2,5 and acetonitrile (70:30) for the assay methodology by HPLC-UV. The results found from the parameters of specificity, linearity, accuracy, precision, quantification and detection limits and stability in the methodologies validations confirm that they were adequate for the purpose proposed. The methodologies developed and validated were applied in Olanzapine determination in several formulation propositions which have been developed and they assisted the pharmacotechnical development team in the definition of the best olanzapine formulation in the 2.5mg strength. |
id |
UFG-2_c5803284dc06797c59b33a497d1be411 |
---|---|
oai_identifier_str |
oai:repositorio.bc.ufg.br:tde/2087 |
network_acronym_str |
UFG-2 |
network_name_str |
Repositório Institucional da UFG |
repository_id_str |
|
spelling |
LIMA, Eliana Martinshttp://lattes.cnpq.br/7248774319455970http://lattes.cnpq.br/3099392420635562MOURA, Julliana Rodrigues2014-07-29T16:11:45Z2010-10-182009-12-14MOURA, Julliana Rodrigues. Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets. 2009. 41 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2009.http://repositorio.bc.ufg.br/tede/handle/tde/2087ark:/38995/00130000002dnOlanzapine is an antipsychotic active ingredient and its marketing in Brazil, in the form of terminated product, is protected by patent up to 2011. As it is recent in the pharmaceutical market and there is not a methodology described in officials forms that is capable of assuring the quality of new formulations, the objective of this paper was to characterize Olanzapine physical-chemical parameters, to develop and validate, in accordance with RE N°899, from May 29 th 2003, the analytical methodology for assay and dissolution and to apply the developed and validated methodologies in the pharmacotechnical development of tablets. It was characterized some physicalchemical parameters of solubility and of light absorption (from 200 to 400nm) in several solvents and it was developed and validated assay and dissolution methodologies by spectrophotometry with ultraviolet detection (UV) and the assay by high efficiency liquid chromatography with ultraviolet detection (HPLC-UV) for the quantification of olanzapine present in film coated tablets of 2.5, 5.0 and 10.0mg. The active ingredient presented a low solubility in water and the wave lengths of maximum light absorption were within the range of 254 and 273nm. For the dissolution methodology by UV spectrophotometry, the parameters were chloride acid 0.1 mol/L as the dissolution media, volume of 1,000mL (5 and 10mg of Olanzapine) and 500mL (2.5mg of Olanzapine), apparatus II (paddles) and a rotation of 50 rpm. The spectrophotometric parameters were chloride acid 0.1 mol/L as blank and 259nm of wave length. For the assay methodology by UV spectrophotometry, it was used as a solvent and as a blank solution chloride acid 0.1 mol/L and a wave length of 259nm. It was used a ProStar 210 UV/VIS VARIAN high efficient liquid chromatographer, a C18 (150x4,6)mm 5μm column in room temperature (25ºC), a flux of 0,8mL/min, a wave length of 254nm and a mobile phase constituted of a mixture of monobasic potassium phosphate buffer 0,01 mol/L pH 2,5 and acetonitrile (70:30) for the assay methodology by HPLC-UV. The results found from the parameters of specificity, linearity, accuracy, precision, quantification and detection limits and stability in the methodologies validations confirm that they were adequate for the purpose proposed. The methodologies developed and validated were applied in Olanzapine determination in several formulation propositions which have been developed and they assisted the pharmacotechnical development team in the definition of the best olanzapine formulation in the 2.5mg strength.A olanzapina é um fármaco antipsicótico e sua comercialização no Brasil, na forma de produto acabado, está protegida por patente até 2011. Como é recente no mercado farmacêutico e não há descrição da metodologia em formulários oficiais capazes de assegurar a qualidade das novas formulações, o objetivo deste trabalho foi caracterizar os parâmetros físico-químicos da olanzapina, desenvolver e validar, segundo RE N°899, de 29 de maio de 2003, método analítico para doseamento e dissolução e aplicar os métodos desenvolvidos e validados no desenvolvimento farmacotécnico dos comprimidos. Foram caracterizados alguns parâmetros físico-químicos, de solubilidade e de absorção da luz (200 a 400 nm) em diversos solventes e foram desenvolvidos e validados métodos de doseamento e dissolução por espectrofotometria com detecção ultravioleta (UV) e de doseamento por cromatografia líquida de alta eficiência com detecção ultravioleta (HPLC-UV) para quantificação de olanzapina presente em comprimidos revestidos de 2,5, 5,0 e 10,0 mg. O fármaco apresentou baixa solubilidade em água e os comprimentos de onda de máxima absorção da luz ficaram entre 254 e 273 nm. Para o método de dissolução por espectrofotometria UV, os melhores parâmetros foram ácido clorídrico 0,1 mol/L como meio de dissolução, volume de 1.000 mL (5 e 10 mg de Olanzapina) e 500mL (2,5mg de Olanzapina), aparato II (pás) e rotação de 50rpm. Os parâmetros espectrofotométricos foram ácido clorídrico 0,1 mol/L como branco e 259nm de comprimento de onda. Para o método de doseamento por espectrofotometria UV foi utilizado como solvente e solução branco ácido clorídrico 0,1 mol/L e comprimento de onda de 259 nm. Foi utilizado cromatógrafo líquido de alta eficiência ProStar 210 UV/VIS VARIAN, coluna C18 (150x4,6) mm 5μm a temperatura ambiente (25ºC), fluxo de 0,8mL/min, comprimento de onda de 254 nm e fase móvel constituída por uma mistura de tampão fosfato de potássio monobásico 0,01 mol/L pH 2,5 e acetonitrila (70:30) para o método de doseamento por HPLC-UV. Os resultados encontrados dos parâmetros de especificidade, linearidade, exatidão, precisão, limites de quantificação e detecção e estabilidade nas validações dos métodos confirmam que os mesmos foram adequados para a finalidade proposta. Os métodos desenvolvidos e validados foram aplicados na determinação de olanzapina em várias propostas de formulações que foram desenvolvidas e auxiliou a equipe de desenvolvimento farmacotécnico na definição da melhor formulação da olanzapina na concentração de 2,5mg.Made available in DSpace on 2014-07-29T16:11:45Z (GMT). No. of bitstreams: 1 Dissertacao Julliana Rodrigues Moura.pdf: 204207 bytes, checksum: 56a1561a44aeb00b316511d72cd22e73 (MD5) Previous issue date: 2009-12-14application/pdfhttp://repositorio.bc.ufg.br/TEDE/retrieve/3335/Dissertacao%20Julliana%20Rodrigues%20Moura.pdf.jpgporUniversidade Federal de GoiásMestrado em Ciências FarmacêuticasUFGBRCiências da Saúde - FarmáciaOlanzapinaHPLCDesenvolvimento de MétodoValidaçãoOlanzapineHPLCMethodology DevelopmentValidationCNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIADesenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapinaDevelopment and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tabletsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGORIGINALDissertacao Julliana Rodrigues Moura.pdfapplication/pdf204207http://repositorio.bc.ufg.br/tede/bitstreams/01b01ccb-57e7-4f95-8240-573df7734cd0/download56a1561a44aeb00b316511d72cd22e73MD51THUMBNAILDissertacao Julliana Rodrigues Moura.pdf.jpgDissertacao Julliana Rodrigues Moura.pdf.jpgGenerated Thumbnailimage/jpeg1943http://repositorio.bc.ufg.br/tede/bitstreams/51829d5c-29db-484a-9016-368f898f9cf4/downloadcc73c4c239a4c332d642ba1e7c7a9fb2MD52tde/20872014-07-30 03:04:41.569open.accessoai:repositorio.bc.ufg.br:tde/2087http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2014-07-30T06:04:41Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)false |
dc.title.por.fl_str_mv |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina |
dc.title.alternative.eng.fl_str_mv |
Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets |
title |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina |
spellingShingle |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina MOURA, Julliana Rodrigues Olanzapina HPLC Desenvolvimento de Método Validação Olanzapine HPLC Methodology Development Validation CNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIA |
title_short |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina |
title_full |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina |
title_fullStr |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina |
title_full_unstemmed |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina |
title_sort |
Desenvolvimento e validação de metodologia analítica aplicável ao desenvolvimento farmacotécnico de comprimidos de olanzapina |
author |
MOURA, Julliana Rodrigues |
author_facet |
MOURA, Julliana Rodrigues |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
LIMA, Eliana Martins |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/7248774319455970 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/3099392420635562 |
dc.contributor.author.fl_str_mv |
MOURA, Julliana Rodrigues |
contributor_str_mv |
LIMA, Eliana Martins |
dc.subject.por.fl_str_mv |
Olanzapina HPLC Desenvolvimento de Método Validação |
topic |
Olanzapina HPLC Desenvolvimento de Método Validação Olanzapine HPLC Methodology Development Validation CNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIA |
dc.subject.eng.fl_str_mv |
Olanzapine HPLC Methodology Development Validation |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS DA SAUDE::FARMACIA::FARMACOTECNIA |
description |
Olanzapine is an antipsychotic active ingredient and its marketing in Brazil, in the form of terminated product, is protected by patent up to 2011. As it is recent in the pharmaceutical market and there is not a methodology described in officials forms that is capable of assuring the quality of new formulations, the objective of this paper was to characterize Olanzapine physical-chemical parameters, to develop and validate, in accordance with RE N°899, from May 29 th 2003, the analytical methodology for assay and dissolution and to apply the developed and validated methodologies in the pharmacotechnical development of tablets. It was characterized some physicalchemical parameters of solubility and of light absorption (from 200 to 400nm) in several solvents and it was developed and validated assay and dissolution methodologies by spectrophotometry with ultraviolet detection (UV) and the assay by high efficiency liquid chromatography with ultraviolet detection (HPLC-UV) for the quantification of olanzapine present in film coated tablets of 2.5, 5.0 and 10.0mg. The active ingredient presented a low solubility in water and the wave lengths of maximum light absorption were within the range of 254 and 273nm. For the dissolution methodology by UV spectrophotometry, the parameters were chloride acid 0.1 mol/L as the dissolution media, volume of 1,000mL (5 and 10mg of Olanzapine) and 500mL (2.5mg of Olanzapine), apparatus II (paddles) and a rotation of 50 rpm. The spectrophotometric parameters were chloride acid 0.1 mol/L as blank and 259nm of wave length. For the assay methodology by UV spectrophotometry, it was used as a solvent and as a blank solution chloride acid 0.1 mol/L and a wave length of 259nm. It was used a ProStar 210 UV/VIS VARIAN high efficient liquid chromatographer, a C18 (150x4,6)mm 5μm column in room temperature (25ºC), a flux of 0,8mL/min, a wave length of 254nm and a mobile phase constituted of a mixture of monobasic potassium phosphate buffer 0,01 mol/L pH 2,5 and acetonitrile (70:30) for the assay methodology by HPLC-UV. The results found from the parameters of specificity, linearity, accuracy, precision, quantification and detection limits and stability in the methodologies validations confirm that they were adequate for the purpose proposed. The methodologies developed and validated were applied in Olanzapine determination in several formulation propositions which have been developed and they assisted the pharmacotechnical development team in the definition of the best olanzapine formulation in the 2.5mg strength. |
publishDate |
2009 |
dc.date.issued.fl_str_mv |
2009-12-14 |
dc.date.available.fl_str_mv |
2010-10-18 |
dc.date.accessioned.fl_str_mv |
2014-07-29T16:11:45Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
MOURA, Julliana Rodrigues. Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets. 2009. 41 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2009. |
dc.identifier.uri.fl_str_mv |
http://repositorio.bc.ufg.br/tede/handle/tde/2087 |
dc.identifier.dark.fl_str_mv |
ark:/38995/00130000002dn |
identifier_str_mv |
MOURA, Julliana Rodrigues. Development and validation of an analytical methodology applicable to the pharmacotechnical development of olanzapine tablets. 2009. 41 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2009. ark:/38995/00130000002dn |
url |
http://repositorio.bc.ufg.br/tede/handle/tde/2087 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.publisher.program.fl_str_mv |
Mestrado em Ciências Farmacêuticas |
dc.publisher.initials.fl_str_mv |
UFG |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Ciências da Saúde - Farmácia |
publisher.none.fl_str_mv |
Universidade Federal de Goiás |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFG instname:Universidade Federal de Goiás (UFG) instacron:UFG |
instname_str |
Universidade Federal de Goiás (UFG) |
instacron_str |
UFG |
institution |
UFG |
reponame_str |
Repositório Institucional da UFG |
collection |
Repositório Institucional da UFG |
bitstream.url.fl_str_mv |
http://repositorio.bc.ufg.br/tede/bitstreams/01b01ccb-57e7-4f95-8240-573df7734cd0/download http://repositorio.bc.ufg.br/tede/bitstreams/51829d5c-29db-484a-9016-368f898f9cf4/download |
bitstream.checksum.fl_str_mv |
56a1561a44aeb00b316511d72cd22e73 cc73c4c239a4c332d642ba1e7c7a9fb2 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFG - Universidade Federal de Goiás (UFG) |
repository.mail.fl_str_mv |
tasesdissertacoes.bc@ufg.br |
_version_ |
1815172508161146880 |